# The promoting effects of digital targeted cognitive training in medication treatment for children with ADHD: a randomized controlled trial.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12219606</article-id><article-id pub-id-type="pmid">40598377</article-id>
<article-id pub-id-type="publisher-id">4192</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04192-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The promoting effects of digital targeted cognitive training in medication treatment for children with ADHD: a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dang</surname><given-names>Chen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Xiangsheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Guisen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Shaogen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jianzhao</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Yike</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Siqi</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ziqi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Xiaohui</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yufeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaoyi</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Jian</given-names></name><address><email>yangjian1306@sina.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Changming</given-names></name><address><email>superwcm@163.com</email></address><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Sun</surname><given-names>Li</given-names></name><address><email>sunlioh@bjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rzcwg85</institution-id><institution-id institution-id-type="GRID">grid.459847.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0615</institution-id><institution>Peking University Sixth Hospital, Peking University Institute of Mental Health, </institution></institution-wrap>Beijing, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rzcwg85</institution-id><institution-id institution-id-type="GRID">grid.459847.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0615</institution-id><institution>NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), </institution></institution-wrap>Beijing, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zw6et16</institution-id><institution-id institution-id-type="GRID">grid.418633.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1771 7032</institution-id><institution>Department of Neurology, </institution><institution>Children&#x02019;s Hospital Affiliated to Capital Institute of Pediatrics, </institution></institution-wrap>Beijing, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zw6et16</institution-id><institution-id institution-id-type="GRID">grid.418633.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1771 7032</institution-id><institution>Department of Child Health, </institution><institution>Children&#x02019;s Hospital Affiliated to Capital Institute of Pediatrics, </institution></institution-wrap>Beijing, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053qy4437</institution-id><institution-id institution-id-type="GRID">grid.411610.3</institution-id><institution>Department of Pediatrics, </institution><institution>Beijing Friendship Hospital Affiliated to Capital Medical University, </institution></institution-wrap>Beijing, China </aff><aff id="Aff6"><label>6</label>Beijing Wispirit Technology Co., Ltd, Beijing, China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013xs5b60</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution>Beijing Luhe Hospital, Capital Medical University, </institution></institution-wrap>Beijing, China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013xs5b60</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution>College of Biomedical Engineering, </institution><institution>Capital Medical University, </institution></institution-wrap>Beijing, China </aff><aff id="Aff9"><label>9</label>Jingtong Brain Research Laboratory, Beijing, China </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>371</elocation-id><history><date date-type="received"><day>6</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par14">Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder often managed with medication. Improving cognitive functions alongside medication treatment is crucial for better outcomes. This study mainly aimed to investigate the therapeutic effects of combining digitally targeted cognitive training with medication compared to medication monotherapy on ADHD core symptoms. We hypothesized that targeted cognitive training could enhance treatment efficacy when combined with medication.</p></sec><sec><title>Methods</title><p id="Par15">This was a randomized parallel-group controlled trial. A total of 124 children with ADHD were randomly allocated to two groups: 64 received medication treatment alone (M), including atomoxetine (ATX) and methylphenidate (MPH); 60 received targeted cognitive training combined with medication (TCT&#x02009;+&#x02009;M), including TCT&#x02009;+&#x02009;ATX and TCT&#x02009;+&#x02009;MPH. Both groups received 8&#x000a0;weeks of treatment. The primary outcome was the changes in ADHD core symptoms measured by the ADHD Rating Scale (ADHD-RS). The secondary outcomes were parent-reported ecological executive functions, social functions, and laboratory cognitive functions.</p></sec><sec><title>Results</title><p id="Par16">Main results: When compared with M treatment, the TCT&#x02009;+&#x02009;M treatment did not show significant greater improvements in ADHD core symptoms, ecological executive functions, social functions, or laboratory cognitive functions. Post-hoc exploratory analysis results: (1) In patients who received ATX treatment, TCT&#x02009;+&#x02009;ATX led to greater improvement in ADHD-RS total, inattention, and hyperactivity/impulsivity symptoms. Similar between-group differences were observed in ecological executive functions, and the improvements were significantly correlated with changes of ADHD core symptoms. (2) In patients who received MPH treatment, no significant differences in the improvement of primary or secondary outcomes were observed between MPH monotherapy and TCT&#x02009;+&#x02009;MPH groups.</p></sec><sec><title>Conclusions</title><p id="Par17">These findings demonstrated that, in comparison to medication monotherapy, the TCT&#x02009;+&#x02009;M treatment did not lead to more improvements in the core symptoms of ADHD, nor did it show superiority in other secondary outcomes. Specifically in children treated with atomoxetine, there&#x02019;s a potential promoting effect of targeted cognitive training on medication treatment in terms of the alleviation of ADHD core symptoms.</p></sec><sec><title>Trial registration</title><p id="Par18">This study was pre-registered with the Chinese Clinical Trial Registry under the identifier ChiCTR2100043525.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04192-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>ADHD</kwd><kwd>Medication treatment</kwd><kwd>Targeted cognitive training</kwd><kwd>Ecological executive functions</kwd></kwd-group><funding-group><award-group><funding-source><institution>the Capital's Funds for Health Improvement and Research</institution></funding-source><award-id>Xiangsheng Luo, 2024-4-21210</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Beijing Municipal Hospital Research and Development Project</institution></funding-source><award-id>Xiangsheng Luo, PX2024067</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China (National Science Foundation of China)</institution></funding-source><award-id>82271579 [Yang]</award-id><award-id>82371549 [Sun]</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Key Scientific Research Projects of Capital Health Development</institution></funding-source><award-id>2020-1-4111 [Sun]</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par38">Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by three core symptoms, including developmentally inappropriate inattention, hyperactivity, and impulsivity [<xref ref-type="bibr" rid="CR1">1</xref>]. Approximately 6.4% of children and adolescents was affected by ADHD in China [<xref ref-type="bibr" rid="CR2">2</xref>], with 43% of individuals experiencing persistent symptoms into adulthood [<xref ref-type="bibr" rid="CR3">3</xref>]. ADHD significantly disrupts an individual&#x02019;s academic performance, work productivity, and daily functioning, imposing a substantial burden on families and communities [<xref ref-type="bibr" rid="CR4">4</xref>].
</p><p id="Par39">Currently, medication stands as the primary approach for managing clinical symptoms in individuals with ADHD [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. In China, the two medications prescribed for ADHD are methylphenidate (MPH) and atomoxetine (ATX). MPH reaches its therapeutic effects by elevating dopamine concentration in the striatum and prefrontal cortex, as well as increasing norepinephrine levels in the prefrontal cortex [<xref ref-type="bibr" rid="CR8">8</xref>]. In contrast, ATX boosts norepinephrine and dopamine levels specifically in the prefrontal cortex but not in the striatum [<xref ref-type="bibr" rid="CR9">9</xref>]. Despite their different mechanisms of action, long-term intervention studies have indicated significant improvements in the core symptoms of ADHD with both medications [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par40">Nevertheless, there remains a need for further enhancement of the therapeutic effects of ADHD medication, particularly in relation to cognitive functions. For instance, some meta-analyses showed that compared to placebo, MPH does improve a broad range of cognitive functions in patients with ADHD [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. However, a more recent meta-analysis indicated that significant dosing effects of MPH were only found in lower-order cognitive functions like (baseline speed, variability in responding, nonexecutive memory), with greater enhancement of functioning with increasing dose. No dosing effects were found for higher-order cognitive functions (executive memory, inhibitory control, and cognitive flexibility) [<xref ref-type="bibr" rid="CR14">14</xref>]. For ATX, one study reported that although 10&#x000a0;weeks of ATX treatment led to a noticeable improvement in ADHD symptoms, there was no significant improvement observed in inhibitory functions [<xref ref-type="bibr" rid="CR15">15</xref>]. Amidst endeavors to enhance cognitive performance, cognitive training has demonstrated its efficacy over the last two decades [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. However, two recent meta-analyses indicated that cognitive training alone did not have a significant effect on the core symptoms of ADHD or their cognitive functions [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Westwood et al. (2023) found significant improvements only in verbal and visual-spatial working memory following cognitive training; however, these positive effects were no longer statistically significant when contrasted to semi-active control groups or proper blinding was implemented [<xref ref-type="bibr" rid="CR19">19</xref>]. These results may be influenced by the relatively rigid and uniform content (i.e., single-component or fixed multi-component) of cognitive training employed in previous studies.</p><p id="Par41">Individuals with ADHD exhibit significant variability in impairments across cognitive domains [<xref ref-type="bibr" rid="CR20">20</xref>]. Fixed component cognitive training, where the training content is uniform for all participants, may not fully address such heterogeneous cognitive deficiencies present in ADHD, constraining their ability to effectively alleviate clinical symptoms [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, it is essential to first measure which dimensions are impaired in children with ADHD compared to healthy control children of the same age. Subsequent interventions should then target these specific impaired cognitive functions, employing more tailored cognitive training methods. Studies have suggested that the combination of cognitive training and medication treatment has demonstrated superior therapeutic effects compared to medication alone [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Therefore, compared with medication treatment alone, combining targeted cognitive training with medication treatment may result in better therapeutic effects in patients with ADHD.</p><p id="Par42">In recent years, the widespread availability of personal computers in households has facilitated the acceptance of online digital cognitive training as a preferred method for delivering interventions. This approach enables clinicians to effectively monitor patients&#x02019; training routines through the analysis of their records and facilitates timely communication during the intervention process, thereby enhancing compliance and overall intervention efficacy. Kollins et al. (2020) conducted a 1-month intervention on 348 children with ADHD using AKL-T01, the first digital cognitive training program approved by the US Food and Drug Administration for ADHD treatment. Following the intervention, significant improvements in attention function were observed among the patients [<xref ref-type="bibr" rid="CR24">24</xref>]. In our recent study, 80 children with ADHD completed 3&#x000a0;months of digital cognitive training (The Focus Pocus, Australia). By the end of treatment, parent-rated symptoms of attention-deficit and hyperactivity/impulsivity significantly decreased [<xref ref-type="bibr" rid="CR25">25</xref>]. These findings underscore the considerable significance of digitalizing cognitive training in the treatment of ADHD.</p><p id="Par43">Up to now, there are no studies that have integrated medication with digitally targeted cognitive training for the treatment of ADHD. The current study aims to combine digitally targeted cognitive training with medication treatment to investigate differences in potential therapeutic effects of combination therapy and medication monotherapy on ADHD core symptoms, ecological executive function, laboratory cognitive function assessments, and social functioning. We hypothesized that (1) combination therapy might lead to more pronounced improvements in core symptoms of ADHD compared to medication monotherapy and (2) ecological executive function, laboratory cognitive function, and social functioning improvements in ADHD patients receiving combination therapy may also surpass those in the medication monotherapy group, and these enhancements may be significantly related to ADHD symptoms.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participants</title><p id="Par44">A total of 200 eligible ADHD patients were recruited, 160 were included and randomized, and 124 completed the 8-week intervention (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The study lasted from June 2021 to December 2023. During early enrollment (June 2021 to November 2022), the dropout rate was high (31/105,&#x02009;~&#x02009;30%) due to the COVID-19 pandemic. In the middle-to-late period (December 2022 to December 2023), the dropout rate significantly decreased (5/55,&#x02009;~&#x02009;9%). The mean age of the participants was 9.4&#x000a0;years old (standard deviation: 1.5, range: 6.0&#x02013;13.7), of which 111 were male (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The participants were recruited from the pediatric psychiatric outpatient of Peking University Sixth Hospital and Capital Institute of Pediatrics. The ethics committees of Peking University Sixth Hospital and Capital Institute of Pediatrics approved this study. Children and their guardians signed the informed consent forms.<fig id="Fig1"><label>Fig. 1</label><caption><p>Diagram of participant flow</p></caption><graphic xlink:href="12916_2025_4192_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographics and baseline clinical characteristics of all participants (mean&#x02009;&#x000b1;&#x02009;standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">TCT&#x02009;+&#x02009;Medication treatment</th><th align="left">Medication treatment</th><th align="left"><bold><italic>t</italic></bold>/<bold><italic>&#x003c7;</italic></bold><sup>2</sup></th><th align="left"><bold><italic>p</italic></bold></th></tr></thead><tbody><tr><td align="left"><italic>N</italic></td><td align="left">60</td><td align="left">64</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Male/female</td><td align="left">53/7</td><td align="left">58/6</td><td char="." align="char">0.173</td><td char="." align="char">0.677</td></tr><tr><td align="left">Age (years)</td><td align="left">9.4&#x02009;&#x000b1;&#x02009;1.4</td><td align="left">9.5&#x02009;&#x000b1;&#x02009;1.7</td><td char="." align="char">&#x02009;&#x02212;&#x02009;0.412</td><td char="." align="char">0.681</td></tr><tr><td align="left">IQ</td><td align="left">108.1&#x02009;&#x000b1;&#x02009;13.9</td><td align="left">110.2&#x02009;&#x000b1;&#x02009;14.4</td><td char="." align="char">&#x02009;&#x02212;&#x02009;0.827</td><td char="." align="char">0.410</td></tr><tr><td align="left" colspan="5"><bold><italic>ADHD core symptoms</italic></bold></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">34.2&#x02009;&#x000b1;&#x02009;8.9</td><td align="left">32.4&#x02009;&#x000b1;&#x02009;6.7</td><td char="." align="char">1.259</td><td char="." align="char">0.211</td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">19.5&#x02009;&#x000b1;&#x02009;4.5</td><td align="left">18.8&#x02009;&#x000b1;&#x02009;3.3</td><td char="." align="char">1.005</td><td char="." align="char">0.317</td></tr><tr><td align="left">&#x02003;Hyperactivity/impulsivity</td><td align="left">14.7&#x02009;&#x000b1;&#x02009;5.7</td><td align="left">13.6&#x02009;&#x000b1;&#x02009;5.0</td><td char="." align="char">1.122</td><td char="." align="char">0.264</td></tr><tr><td align="left" colspan="5"><bold><italic>Ecological executive functions</italic></bold></td></tr><tr><td align="left">&#x02003;Standardized GEC</td><td align="left">2.15&#x02009;&#x000b1;&#x02009;0.27</td><td align="left">2.09&#x02009;&#x000b1;&#x02009;0.27</td><td char="." align="char">1.019</td><td char="." align="char">0.311</td></tr><tr><td align="left">&#x02003;Standardized BRI</td><td align="left">1.82&#x02009;&#x000b1;&#x02009;0.36</td><td align="left">1.82&#x02009;&#x000b1;&#x02009;0.36</td><td char="." align="char">0.023</td><td char="." align="char">0.982</td></tr><tr><td align="left">&#x02003;Standardized MI</td><td align="left">2.35&#x02009;&#x000b1;&#x02009;0.26</td><td align="left">2.27&#x02009;&#x000b1;&#x02009;0.28</td><td char="." align="char">1.680</td><td char="." align="char">0.096</td></tr><tr><td align="left" colspan="5"><bold><italic>Socical functions</italic></bold></td></tr><tr><td align="left">&#x02003;WFIRS total</td><td align="left">39.00&#x02009;&#x000b1;&#x02009;12.90</td><td align="left">38.86&#x02009;&#x000b1;&#x02009;11.75</td><td char="." align="char">0.063</td><td char="." align="char">0.950</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>TCT&#x000a0;</italic>targeted cognitive training,&#x000a0;<italic>IQ&#x000a0;</italic>intelligence quotient,&#x000a0;<italic>ADHD-RS&#x000a0;</italic>ADHD rating scale,&#x000a0;<italic>BRIEF&#x000a0;</italic>the Behavior Rating Inventory of Executive Function,&#x000a0;<italic>GEC&#x000a0;</italic>global executive composite,&#x000a0;<italic>BRI&#x000a0;</italic>Behavioral Regulation Index,&#x000a0;<italic>MI&#x000a0;</italic>Metacognition Index,&#x000a0;<italic>WFIRS&#x000a0;</italic>Weiss Functional Impairment Rating Scale</p></table-wrap-foot></table-wrap></p><p id="Par45">The inclusion criteria were as follows: (1) diagnosed by a senior psychiatrist and met the diagnostic criteria for ADHD in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) after a semi-structured interview with the parents using Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL); (2) full-scale intelligence quotient (IQ) exceeding 80, as assessed using the Chinese version of the Wechsler Intelligence Scale for Children&#x02014;Fourth Edition (WISC-IV); (3) aged 6&#x02013;16&#x000a0;years; (4) had never taken any ADHD medication or underwent medication washout before enrollment (at least five half-lives of medication discontinuation).</p><p id="Par46">The exclusion criteria included the following: (1) childhood schizophrenia, mood disorder, anxiety disorder, intellectual disabilities, autism spectrum disorder, epilepsy, and other neurological organic diseases; (2) significant somatic abnormalities or significant visual or auditory impairment; (3) current participation in other non-medication treatments.</p></sec><sec id="Sec4"><title>Procedure</title><p id="Par47">The study procedure, the number of included and excluded cases, and the dropout status were illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The type of medication was determined based primarily on the patient&#x02019;s individual circumstances, including clinical symptoms, body weight, and past experiences with side effects. This decision was made through a clinical process involving the patient, their parents, and the physician during outpatient consultations. Following the confirmation of medication type, participants were randomly assigned to two parallel groups (medication treatment with or without cognitive training) in a 1:1 ratio using a random chart method, while ensuring that age, sex, and disease severity were matched between the groups. The group assignment was not blinded to either the researchers or the participants. Authors S.Z. and Z.L. (respectively affiliated with Peking University Sixth Hospital and Capital Institute of Pediatrics) generated the randomized allocation sequence, conducted participant enrollment, and performed intervention assignment at their respective institutions. After randomized into either the medication monotherapy (M group) or targeted cognitive training&#x02009;+&#x02009;medication combination groups (TCT&#x02009;+&#x02009;M group), the participants in the two groups were assigned distinct treatment protocols, and both underwent an 8-week treatment duration. Among participants in this trial, not all were drug-na&#x000ef;ve before the pre-assessment. For those who had previously taken ADHD medication, a wash-out period (at least five half-lives of medication discontinuation) was ensured before the pre-assessment, after which the medication was restarted. Medication treatment and targeted cognitive training started simultaneously and both continued until the post-intervention assessment. The intended conclusion of the intervention was at the end of the 8-week treatment period. The two groups&#x02019; core clinical symptoms, ecological executive function, laboratory cognitive function, and social functioning were evaluated at baseline and after 8&#x000a0;weeks of treatment. Participants were considered to have dropped out if any of the following conditions occurred: (1) the patient or parents voluntarily withdrew from the study; (2) the patients received additional treatments during the study (e.g., psychotherapy or biofeedback); (3) the total number of training sessions was fewer than 80% of the planned training sessions (i.e., less than 32 sessions, as the initial training goal was set at 40 sessions over 8&#x000a0;weeks, with 5 sessions per week); (4) discontinued medication for a continuous period exceeding 7&#x000a0;days. There were no significant changes to methods after the trial commenced.</p></sec><sec id="Sec5"><title>Intervention</title><sec id="Sec6"><title>M group</title><p id="Par48">Children in this group received 8&#x000a0;weeks of medication treatment with either methylphenidate or atomoxetine. Following treatment initiation, the starting dose was gradually titrated to the optimal treatment dose, which was then maintained until the 8-week intervention. The starting dose of methylphenidate (Concerta; Janssen Pharmaceuticals, Inc., Xi&#x02019;an, Shaanxi, China; <ext-link ext-link-type="uri" xlink:href="http://www.xian-janssen.com.cn">http://www.xian-janssen.com.cn</ext-link>) typically began at 18&#x000a0;mg/day and was adjusted every 7&#x000a0;days based on efficacy and side effects, with increments or decrements of 18&#x000a0;mg/day, up to a maximum dose of 54&#x000a0;mg/day. The starting dose of atomoxetine (Strattera; LILLY S.A., Shanghai, China; <ext-link ext-link-type="uri" xlink:href="https://www.lillymedical.cn/zh-cn/cns/Strattera">https://www.lillymedical.cn/zh-cn/cns/Strattera</ext-link>) typically commenced at 0.5&#x000a0;mg/kg per day based on body weight, with adjustments made every 7&#x000a0;days according to efficacy and side effects, up to a maximum daily dose of 1.2&#x000a0;mg/kg or 100&#x000a0;mg. The time required to titrate to the optimal medication dose varied depending on individual circumstances, typically taking 2 to 4&#x000a0;weeks. At the 8-week intervention, the mean dose of methylphenidate in the medication monotherapy group was 23.26&#x02009;&#x000b1;&#x02009;8.49&#x000a0;mg per day, and the dose-to-weight ratio was 0.67&#x02009;&#x000b1;&#x02009;0.19&#x000a0;mg/kg per day. The mean dose of atomoxetine in the medication monotherapy group was 31.25&#x02009;&#x000b1;&#x02009;11.71&#x000a0;mg per day, and the dose-to-weight ratio was 0.89&#x02009;&#x000b1;&#x02009;0.23&#x000a0;mg/kg per day.</p></sec><sec id="Sec7"><title><italic>TCT</italic>&#x02009;+&#x02009;<italic>M group</italic></title><p id="Par49">In addition to the medication treatment provided to the M group, the TCT&#x02009;+&#x02009;M group also underwent an 8-week digitally targeted cognitive training concurrently. In the TCT&#x02009;+&#x02009;M group, the mean dose of methylphenidate was 24.5&#x02009;&#x000b1;&#x02009;7.54&#x000a0;mg per day, and the dose-to-weight ratio was 0.70&#x02009;&#x000b1;&#x02009;0.18&#x000a0;mg/kg per day. The mean dose of atomoxetine was 30.75&#x02009;&#x000b1;&#x02009;12.11&#x000a0;mg per day, and the dose-to-weight ratio was 0.87&#x02009;&#x000b1;&#x02009;0.26&#x000a0;mg/kg per day. Before the start of cognitive training, every participant was guided to complete a cognitive function assessment at baseline, including perception (time selection task, paper folding task, random dot motion task), attention (flanker task, vigilance task), memory (<italic>K</italic>-score task, digit span forward task), executive function (go/no-go task and digit span backward task), and social cognition (emotion recognition task) tasks. Then, an individualized training plan was constructed based on the results of these cognitive function assessments. The training program was developed collaboratively by the research team at Peking University Sixth Hospital and Beijing Wispirit Technology Co., Ltd. (<ext-link ext-link-type="uri" xlink:href="http://www.66nao.com">www.66nao.com</ext-link>). More details are provided in Additional file 1: Supplementary Method 1 (for a comprehensive explanation of the tasks), Supplementary Method 2 (for steps for developing personalized training plans), and Supplementary Fig. 1&#x000a0;(for an overview of the training procedure).</p><p id="Par50">Given the interactive nature of some tasks, parents were asked during enrollment to confirm the availability of a tablet for home training, which they reported as consistently convenient. The training program comprised 40 sessions conducted 5&#x000a0;days a week over an 8-week intervention period, with each daily session including five distinct cognitive tasks that lasted 2&#x000a0;min and were repeated three times, totaling 30&#x000a0;min of training per day. This framework included 33 tasks targeting five cognitive domains: 3 for perception, 8 for attention, 9 for memory, 12 for executive function, and 1 for social recognition, ensuring consistency with the cognitive domains assessed at both baseline and post-intervention. To enable comparisons of the training program&#x02019;s efficacy and control for practice effects, assessment tasks and their corresponding training tasks within the same cognitive domain were presented using distinct psychological paradigms. To standardize the training process, instructions for all tasks were presented in both text and image formats prior to the start of each training task.</p><p id="Par51">Task performance was measured through accuracy and response time, with higher performance leading to higher scores; once a target score was reached, a more challenging task was unlocked (self-adaptive). The difficulty adjustment mechanism differed across tasks, with adjustments occurring typically every 3 to 5 trials based on participants&#x02019; performance. Consecutive correct responses increased task difficulty, while consecutive incorrect responses decreased it, promoting a tailored and adaptive cognitive training experience.</p><p id="Par52">To ensure the effectiveness and accuracy of the cognitive training, the process was supervised by hospital physicians, supported by parents assisting with daily training, and supplemented by online demonstrations provided through the training program. This collaborative approach ensured that the training was both properly administered and effective. Throughout the cognitive training period, the doctor supervised the patient&#x02019;s training remotely via the Internet, and prompt reminders were sent when scheduled training sessions were not completed. In addition, the doctor maintained regular communication with the patient&#x02019;s family and made timely adjustments to the patient&#x02019;s training plan based on the periodic training data. For medication management, both M and TCT&#x02009;+&#x02009;M groups maintained regular communication with doctors through clinical appointments scheduled biweekly to monthly. These appointments facilitated the reporting of medication efficacy and side effects.</p></sec></sec><sec id="Sec8"><title>Assessment</title><sec id="Sec9"><title>Primary outcome measures</title><p id="Par53">The ADHD Rating Scale (ADHD-RS) [<xref ref-type="bibr" rid="CR26">26</xref>] was used to assess changes in ADHD symptoms. The scale comprised 18 items, consisting of inattention and hyperactivity/impulsivity subscales. The changes in ADHD-RS scores between baseline and post-intervention, as well as the reduction rates ((baseline&#x02009;&#x02212;&#x02009;post-intervention)/baseline) in ADHD-RS scores, were calculated. The reduction rate was considered a valuable outcome measure, as it accounts for each individual&#x02019;s baseline symptom severity.</p></sec><sec id="Sec10"><title>Secondary outcome measures</title><p id="Par54">Parent-reported ecological executive function was assessed using the parental version of the Behavior Rating Inventory of Executive Function (BRIEF) [<xref ref-type="bibr" rid="CR27">27</xref>], a standardized assessment tool designed to evaluate executive function in children and adolescents aged 5 to 18&#x000a0;years. By providing insights into how executive function impacts daily functioning and behavior, the BRIEF helps clinicians and educators identify strengths and weaknesses. The indices include the General Executive Composite (GEC), Metacognition Index (MI) and Behavioral Regulation Index (BRI). The factors include Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Organization of Materials, and Monitor. Additionally, social functioning was assessed with the parental version of the Weiss Functional Impairment Rating Scale (WFIRS) [<xref ref-type="bibr" rid="CR28">28</xref>]. Ten cognitive tasks were employed to evaluate laboratory cognitive functions, with the same tasks used for both baseline and post-intervention assessments. A detailed description of the assessments utilized was provided in Additional file 1: Supplementary Method 1 (for cognitive tasks) and Supplementary Method 3 (for clinical scales).</p><p id="Par55">The ten cognitive function tasks assessed at baseline to develop targeted training were replicated at post-intervention to serve as the index of changes in cognitive functions. Children completed cognitive tasks in a quiet laboratory room using a tablet computer provided by the researchers. Parents completed all questionnaires online using their personal smartphones during clinic visits. To ensure coherence and consistency in assessment, the same parent rated their children&#x02019;s behaviors at both baseline and post-intervention. Baseline assessments were completed before determining the intervention type (M vs. TCT&#x02009;+&#x02009;M) to prevent selection bias. No changes to the trial outcomes were made after the trial commenced.</p></sec></sec><sec id="Sec11"><title>Statistical analysis</title><p id="Par56">The sample size was determined a priori with an alpha level of 0.05, a power of 0.95, and an effect size of 0.3 (<italic>f</italic>), which indicated a required sample size of 136 participants (G*Power 3.1). To account for a possible dropout rate of 15%, the intended sample size was set at 160. The trial was completed once the target sample size of 160 was achieved. The SPSS 29.0 statistical software package was utilized for statistical analysis of the ADHD symptom scale scores, ecological executive function scores, social functioning scores, and behavior data (including accuracy and reaction time) of laboratory cognitive tasks. Random intercepts linear mixed-effects models (LMM) were used to analyze the primary and secondary outcomes (including ADHD-RS, BRIEF, WFIRS and laboratory cognitive tasks). Missing values were observed only in the laboratory cognitive tasks; due to lockdowns during the COVID-19 pandemic, some participants (N&#x02009;=&#x02009;42) were unable to attend the in-person cognitive task assessments, although they were able to complete the online parent questionnaires. Independent models included group (M vs. TCT&#x02009;+&#x02009;M), time effect (baseline vs. post-intervention), group by time interaction, and participants as random effects, gender, IQ, and age as covariates. LMM was also conducted to compare the reduction rates of ADHD-RS scores between all intervention groups, and group as the fixed effect, subjects as the random effects, gender, IQ, and age as covariates. Cohen <italic>d</italic> was used to estimate the effect size between groups.</p><p id="Par57">Pearson&#x02019;s correlation analysis was employed to explore the relationship between the changes in ADHD core symptoms and that in secondary outcomes. To examine which baseline characteristic could predict the treatment efficacy on ADHD core symptoms (change scores), we employed the Enter method for regression analysis, where all predictors were simultaneously entered into the regression model. Two-tailed tests were performed for all statistical results, and a difference with <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. To control for false discoveries arising from multiple comparisons, we applied the False Discovery Rate (FDR) correction using the Benjamini&#x02013;Hochberg procedure (BHFDR). This method is designed to limit the expected proportion of false positives among the rejected null hypotheses, thereby balancing sensitivity and specificity. We employed the <italic>mafdr</italic> function in MATLAB to obtain adjusted <italic>p</italic>-values. An adjusted <italic>p</italic>-value below the predefined significance threshold (0.05) indicates a statistically significant result after FDR correction.</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Main results</title><p id="Par58">For the primary efficacy outcomes (the change scores and reduction rates of ADHD-RS total, inattention, hyperactivity/impulsivity), the results showed that the least square mean differences (LSMDs) were all not significant (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05), which means the treatment effects between TCT&#x02009;+&#x02009;M and M groups did not differ from each other (see Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). For the ecological executive functions, laboratory cognitive tasks, and social functions, LMM showed that the changes of these measurements were not significant between TCT&#x02009;+&#x02009;M and M groups (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of efficacy comparisons of M group and TCT&#x02009;+&#x02009;M combination group (mean&#x02009;&#x000b1;&#x02009;standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Medication treatment<break/>(<italic>N</italic>&#x02009;=&#x02009;64)</th><th align="left">TCT&#x02009;+&#x02009;Medication treatment<break/>(<italic>N</italic>&#x02009;=&#x02009;60)</th><th align="left">LSMD (95% CI)</th><th align="left"><italic>p</italic></th><th align="left"><italic>p</italic> (FDR)</th></tr></thead><tbody><tr><td align="left" colspan="6"><italic>ADHD-RS (change scores)</italic></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">&#x02009;&#x02212;&#x02009;8.78 (0.98)</td><td align="left">&#x02009;&#x02212;&#x02009;11.08 (1.02)</td><td align="left">2.30 (&#x02212;&#x02009;0.47 to 5.08)</td><td char="." align="char">0.103</td><td char="." align="char">0.340</td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">&#x02009;&#x02212;&#x02009;5.23 (0.57)</td><td align="left">&#x02009;&#x02212;&#x02009;6.43 (0.59)</td><td align="left">1.20 (&#x02212;&#x02009;0.42 to 2.82)</td><td char="." align="char">0.145</td><td char="." align="char">0.340</td></tr><tr><td align="left">&#x02003;Hyperactivity/impulsivity</td><td align="left">&#x02009;&#x02212;&#x02009;3.55 (0.57)</td><td align="left">&#x02009;&#x02212;&#x02009;4.65 (0.59)</td><td align="left">1.10 (&#x02212;&#x02009;0.50 to 2.70)</td><td char="." align="char">0.175</td><td char="." align="char">0.340</td></tr><tr><td align="left" colspan="6"><italic>ADHD-RS (reduction rates, %)</italic></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">26.03 (22.10)</td><td align="left">30.64 (17.89)</td><td align="left">&#x02009;&#x02212;&#x02009;4.60 (&#x02212;&#x02009;11.74 to 2.54)</td><td char="." align="char">0.204</td><td char="." align="char">0.340</td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">25.96 (22.71)</td><td align="left">30.46 (20.09)</td><td align="left">&#x02009;&#x02212;&#x02009;4.54 (&#x02212;&#x02009;12.11 to 3.10)</td><td char="." align="char">0.243</td><td char="." align="char">0.347</td></tr><tr><td align="left">&#x02003;Hyperactivity/impulsivity</td><td align="left">25.06 (29.01)</td><td align="left">27.97 (31.68)</td><td align="left">&#x02009;&#x02212;&#x02009;2.91 (&#x02212;&#x02009;13.65 to 7.84)</td><td char="." align="char">0.593</td><td char="." align="char">0.593</td></tr><tr><td align="left" colspan="6"><italic>BRIEF</italic></td></tr><tr><td align="left">&#x02003;Global executive composite</td><td align="left">&#x02009;&#x02212;&#x02009;0.15 (0.04)</td><td align="left">&#x02009;&#x02212;&#x02009;0.28 (0.04)</td><td align="left">0.12 (0.01 to 0.23)</td><td char="." align="char"><bold>0.032</bold></td><td char="." align="char">0.160</td></tr><tr><td align="left">&#x02003;Behavioral Regulation Index</td><td align="left">&#x02009;&#x02212;&#x02009;0.14 (0.04)</td><td align="left">&#x02009;&#x02212;&#x02009;0.20 (0.04)</td><td align="left">0.06 (&#x02212;&#x02009;0.06 to 0.17)</td><td char="." align="char">0.330</td><td char="." align="char">0.393</td></tr><tr><td align="left">&#x02003;Metacognition Index</td><td align="left">&#x02009;&#x02212;&#x02009;0.16 (0.04)</td><td align="left">&#x02009;&#x02212;&#x02009;0.32 (0.04)</td><td align="left">0.16 (0.04 to 0.28)</td><td char="." align="char"><bold>0.010</bold></td><td char="." align="char">0.100</td></tr><tr><td align="left">&#x02003;WFIRS total</td><td align="left">&#x02009;&#x02212;&#x02009;2.83 (0.66)</td><td align="left">&#x02009;&#x02212;&#x02009;2.92 (0.73)</td><td align="left">0.09 (&#x02212;&#x02009;0.23 to 1.21)</td><td char="." align="char">0.354</td><td char="." align="char">0.393</td></tr></tbody></table><table-wrap-foot><p>Note: Bold fonts indicated that <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <italic>M&#x000a0;</italic>medication,&#x000a0;<italic>TCT&#x000a0;</italic>targeted cognitive training,&#x000a0;<italic>LSMD&#x000a0;</italic>least square mean difference,&#x000a0;<italic>CI&#x000a0;</italic>confidence interval,&#x000a0;<italic>ADHD-RS&#x000a0;</italic>ADHD rating scale,&#x000a0;<italic>BRIEF&#x000a0;</italic>the Behavior Rating Inventory of Executive Function,&#x000a0;<italic>WFIRS&#x000a0;</italic>Weiss Functional Impairment Rating Scale,&#x000a0;<italic>FDR&#x000a0;</italic>False Discovery Rate correction</p></table-wrap-foot></table-wrap></p><p id="Par59">The side effects of medication treatment included nausea and decreased appetite. As illustrated in the participant flow diagram (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), some participants withdrew from the trial due to these side effects. Most participants did not report any side effects from the cognitive training. However, one child expressed extreme frustration when unable to complete a maze task related to sensory functions and subsequently refused further training. After the parent contacted the researchers, the training paradigm was personalized to exclude this specific task and replace it with other tasks within the same cognitive domain, allowing the child to continue with the treatment.</p></sec><sec id="Sec14"><title>Post-hoc exploratory analysis results</title><p id="Par60">Given the different pharmacological mechanisms of MPH and ATX, there might be potential variability in therapeutic effects resulting from different medication types combined with training. Therefore, we subsequently categorized patients into methylphenidate and atomoxetine groups for further analyses. The demographics of the four groups are provided in Additional file 1: Supplementary Table&#x000a0;1.</p><sec id="Sec15"><title>MPH group</title><p id="Par61">The results of LMM showed that LSMDs between TCT&#x02009;+&#x02009;MPH (<italic>N</italic>&#x02009;=&#x02009;33) and MPH (<italic>N</italic>&#x02009;=&#x02009;28) groups were not significant in all measurements including ADHD-RS, BRIEF, WFIRS, and any cognitive tasks (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05; see Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Additional file 1: Supplementary Tables 2&#x02013;4).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of efficacy comparisons of methylphenidate group and targeted cognitive training&#x02009;+&#x02009;methylphenidate combination group (mean&#x02009;&#x000b1;&#x02009;standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">MPH treatment<break/>(<italic>N</italic>&#x02009;=&#x02009;33)</th><th align="left">TCT&#x02009;+&#x02009;MPH treatment<break/>(<italic>N</italic>&#x02009;=&#x02009;28)</th><th align="left">LSMD (95% CI)</th><th align="left"><italic>p</italic></th><th align="left"><italic>p</italic> (FDR)</th></tr></thead><tbody><tr><td align="left" colspan="6"><italic>ADHD-RS (change scores)</italic></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">&#x02009;&#x02212;&#x02009;9.67 (1.39)</td><td align="left">&#x02009;&#x02212;&#x02009;9.54 (1.51)</td><td align="left">&#x02009;&#x02212;&#x02009;0.13 (&#x02212;&#x02009;4.15 to 3.89)</td><td char="." align="char">0.948</td><td char="." align="char">0.960</td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">&#x02009;&#x02212;&#x02009;5.61 (0.85)</td><td align="left">&#x02009;&#x02212;&#x02009;5.54 (0.92)</td><td align="left">&#x02009;&#x02212;&#x02009;0.07 (&#x02212;&#x02009;2.54 to 2.40)</td><td char="." align="char">0.955</td><td char="." align="char">0.960</td></tr><tr><td align="left">&#x02003;Hyperactivity/impulsivity</td><td align="left">&#x02009;&#x02212;&#x02009;4.06 (0.83)</td><td align="left">&#x02009;&#x02212;&#x02009;4.00 (0.90)</td><td align="left">&#x02009;&#x02212;&#x02009;0.06 (&#x02212;&#x02009;2.47 to 2.35)</td><td char="." align="char">0.960</td><td char="." align="char">0.960</td></tr><tr><td align="left" colspan="6"><italic>ADHD-RS (reduction rates, %)</italic></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">30.39 (22.21)</td><td align="left">26.46 (19.49)</td><td align="left">3.93 (&#x02212;&#x02009;14.62 to 6.75)</td><td char="." align="char">0.464</td><td char="." align="char">0.890</td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">28.50 (24.27)</td><td align="left">25.79 (23.84)</td><td align="left">2.72 (&#x02212;&#x02009;14.97 to 9.53)</td><td char="." align="char">0.659</td><td char="." align="char">0.941</td></tr><tr><td align="left">&#x02003;Hyperactivity/impulsivity</td><td align="left">35.05 (25.43)</td><td align="left">27.70 (26.38)</td><td align="left">7.34 (&#x02212;&#x02009;20.87 to 6.18)</td><td char="." align="char">0.191</td><td char="." align="char">0.890</td></tr><tr><td align="left" colspan="6"><italic>BRIEF</italic></td></tr><tr><td align="left">&#x02003;Global executive composite</td><td align="left">&#x02009;&#x02212;&#x02009;0.20 (0.06)</td><td align="left">&#x02009;&#x02212;&#x02009;0.27 (0.06)</td><td align="left">0.07 (&#x02212;&#x02009;0.09 to 0.23)</td><td char="." align="char">0.403</td><td char="." align="char">0.890</td></tr><tr><td align="left">&#x02003;Behavioral Regulation Index</td><td align="left">&#x02009;&#x02212;&#x02009;0.19 (0.06)</td><td align="left">&#x02009;&#x02212;&#x02009;0.14 (0.06)</td><td align="left">&#x02009;&#x02212;&#x02009;0.05 (&#x02212;&#x02009;0.22 to 0.11)</td><td char="." align="char">0.534</td><td char="." align="char">0.890</td></tr><tr><td align="left">&#x02003;Metacognition Index</td><td align="left">&#x02009;&#x02212;&#x02009;0.21 (0.06)</td><td align="left">&#x02009;&#x02212;&#x02009;0.36 (0.07)</td><td align="left">0.14 (&#x02212;&#x02009;0.04 to 0.32)</td><td char="." align="char">0.117</td><td char="." align="char">0.890</td></tr><tr><td align="left">&#x02003;WFIRS total</td><td align="left">&#x02009;&#x02212;&#x02009;3.53 (0.81)</td><td align="left">&#x02009;&#x02212;&#x02009;3.39 (0.75)</td><td align="left">&#x02009;&#x02212;&#x02009;0.14 (&#x02212;&#x02009;0.34 to 1.55)</td><td char="." align="char">0.324</td><td char="." align="char">0.890</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations: MPH&#x000a0;</italic>methylphenidate,&#x000a0;<italic>TCT&#x000a0;</italic>targeted cognitive training,&#x000a0;<italic>LSMD&#x000a0;</italic>least square mean difference,&#x000a0;<italic>CI&#x000a0;</italic>confidence interval,&#x000a0;<italic>ADHD-RS&#x000a0;</italic>ADHD rating scale,&#x000a0;<italic>BRIEF&#x000a0;</italic>the Behavior Rating Inventory of Executive Function,&#x000a0;<italic>WFIRS&#x000a0;</italic>Weiss Functional Impairment Rating Scale,&#x000a0;<italic>FDR&#x000a0;</italic>False Discovery Rate correction</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>ATX group</title><p id="Par62">LMM showed that TCT&#x02009;+&#x02009;ATX treatment (<italic>N</italic>&#x02009;=&#x02009;32) led to greater least squares mean changes in ADHD-RS total, inattention, and hyperactivity/impulsivity (including the change scores and reduction rates) than ATX treatment (<italic>N</italic>&#x02009;=&#x02009;31) (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Cohen <italic>d</italic>&#x02009;&#x02265;&#x02009;0.52; see Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Figs. <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). For the ecological executive functions, LSMDs were significant in GEC and MI scores (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Cohen <italic>d</italic>&#x02009;&#x02265;&#x02009;0.54), which means TCT&#x02009;+&#x02009;ATX led to greater changes than ATX in these measurements. The LSMDs in WFIRS score and measurements of cognitive tasks were not significant between TCT&#x02009;+&#x02009;ATX and ATX groups (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of efficacy comparisons of atomoxetine group and targeted cognitive training&#x02009;+&#x02009;atomoxetine combination group (mean&#x02009;&#x000b1;&#x02009;standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">ATX treatment<break/>(<italic>N</italic>&#x02009;=&#x02009;31)</th><th align="left">TCT&#x02009;+&#x02009;ATX treatment<break/>(<italic>N</italic>&#x02009;=&#x02009;32)</th><th align="left">LSMD (95% CI)</th><th align="left"><italic>p</italic></th><th align="left"><italic>p</italic> (FDR)</th></tr></thead><tbody><tr><td align="left" colspan="6"><italic>ADHD-RS (change scores)</italic></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">&#x02009;&#x02212;&#x02009;7.84 (1.38)</td><td align="left">&#x02009;&#x02212;&#x02009;12.44 (1.36)</td><td align="left">4.60 (0.78 to 8.42)</td><td char="." align="char"><bold>0.019</bold></td><td char="." align="char"><bold>0.042</bold></td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">&#x02009;&#x02212;&#x02009;4.84 (0.76)</td><td align="left">&#x02009;&#x02212;&#x02009;7.22 (0.75)</td><td align="left">2.38 (0.27 to 4.49)</td><td char="." align="char"><bold>0.028</bold></td><td char="." align="char"><bold>0.042</bold></td></tr><tr><td align="left">&#x02003;Hyperactivity/impulsivity</td><td align="left">&#x02009;&#x02212;&#x02009;3.00 (0.77)</td><td align="left">&#x02009;&#x02212;&#x02009;5.22 (0.76)</td><td align="left">2.22 (0.09 to 4.34)</td><td char="." align="char"><bold>0.041</bold></td><td char="." align="char"><bold>0.046</bold></td></tr><tr><td align="left" colspan="6"><italic>ADHD-RS (reduction rates, %)</italic></td></tr><tr><td align="left">&#x02003;ADHD-RS total</td><td align="left">21.53 (21.42)</td><td align="left">34.29 (15.76)</td><td align="left">&#x02009;&#x02212;&#x02009;12.76 (&#x02212;&#x02009;22.05 to 3.46)</td><td char="." align="char"><bold>0.008</bold></td><td char="." align="char"><bold>0.041</bold></td></tr><tr><td align="left">&#x02003;Inattention</td><td align="left">23.32 (21.04)</td><td align="left">34.56 (15.37)</td><td align="left">&#x02009;&#x02212;&#x02009;11.23 (&#x02212;&#x02009;20.34 to 2.13)</td><td char="." align="char"><bold>0.016</bold></td><td char="." align="char"><bold>0.042</bold></td></tr><tr><td align="left">&#x02003;Hyperactivity/Impulsivity</td><td align="left">18.03 (25.66)</td><td align="left">34.62 (24.05)</td><td align="left">&#x02009;&#x02212;&#x02009;16.58 (&#x02212;&#x02009;28.90 to 4.27)</td><td char="." align="char"><bold>0.009</bold></td><td char="." align="char"><bold>0.041</bold></td></tr><tr><td align="left" colspan="6"><italic>BRIEF</italic></td></tr><tr><td align="left">&#x02003;Global executive composite</td><td align="left">&#x02009;&#x02212;&#x02009;0.11 (0.05)</td><td align="left">&#x02009;&#x02212;&#x02009;0.28 (0.05)</td><td align="left">0.17 (0.02 to 0.32)</td><td char="." align="char"><bold>0.031</bold></td><td char="." align="char"><bold>0.042</bold></td></tr><tr><td align="left">&#x02003;Behavioral Regulation Index</td><td align="left">&#x02009;&#x02212;&#x02009;0.09 (0.06)</td><td align="left">&#x02009;&#x02212;&#x02009;0.24 (0.06)</td><td align="left">0.15 (&#x02212;&#x02009;0.01 to 0.30)</td><td char="." align="char">0.061</td><td char="." align="char">0.061</td></tr><tr><td align="left">&#x02003;Metacognition Index</td><td align="left">&#x02009;&#x02212;&#x02009;0.12 (0.06)</td><td align="left">&#x02009;&#x02212;&#x02009;0.30 (0.06)</td><td align="left">0.18 (0.01 to 0.34)</td><td char="." align="char"><bold>0.033</bold></td><td char="." align="char"><bold>0.042</bold></td></tr><tr><td align="left">&#x02003;WFIRS total</td><td align="left">&#x02009;&#x02212;&#x02009;2.12 (0.74)</td><td align="left">&#x02009;&#x02212;&#x02009;2.45 (0.69)</td><td align="left">0.33 (&#x02212;&#x02009;0.58 to 1.41)</td><td char="." align="char">0.204</td><td char="." align="char">0.204</td></tr></tbody></table><table-wrap-foot><p>Note: Bold fonts indicated that <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <italic>ATX&#x000a0;</italic>atomoxetine,&#x000a0;<italic>TCT&#x000a0;</italic>targeted cognitive training,&#x000a0;<italic>LSMD&#x000a0;</italic>least square mean difference,&#x000a0;<italic>CI&#x000a0;</italic>confidence interval,&#x000a0;<italic>ADHD-RS&#x000a0;</italic>ADHD rating scale,&#x000a0;<italic>BRIEF&#x000a0;</italic>the Behavior Rating Inventory of Executive Function,&#x000a0;<italic>WFIRS&#x000a0;</italic>Weiss Functional Impairment Rating Scale,&#x000a0;<italic>FDR&#x000a0;</italic>False Discovery Rate correction</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>ADHD Rating Scale scores of inattention, hyperactivity/impulsivity, and total at baseline and post-intervention for individuals with ADHD who received atomoxetine (<bold>A</bold>&#x02013;<bold>C</bold>) and methylphenidate (<bold>D</bold>&#x02013;<bold>F</bold>). ATX, atomoxetine; TCT, targeted cognitive training; MPH, methylphenidate. Error bar stands for 95% confidence interval</p></caption><graphic xlink:href="12916_2025_4192_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Reduction rate of ADHD Rating Scale scores of inattention, hyperactivity/impulsivity, and total at baseline and post-intervention for individuals with ADHD who received atomoxetine (<bold>A</bold>) and methylphenidate (<bold>B</bold>). ATX, atomoxetine; TCT, targeted cognitive training; MPH, methylphenidate. <italic>*p</italic>&#x02009;&#x0003c;&#x02009;0.05; ns, not significant. Error bar stands for 95% confidence interval</p></caption><graphic xlink:href="12916_2025_4192_Fig3_HTML" id="MO3"/></fig></p><p id="Par63">Based on the aforementioned results, we conducted a correlation analysis between the changes of ecological executive function (GEC and MI) and that in ADHD core symptoms in ATX treatment groups (including ATX and TCT&#x02009;+&#x02009;ATX groups). The results showed that the changes in GEC score were significantly correlated with changes in inattention and ADHD-RS total scores (all <italic>r</italic>&#x02009;&#x02265;&#x02009;0.377, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; see Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). In addition, the changes in MI score were significantly correlated with changes in inattention and ADHD-RS total scores (all <italic>r</italic>&#x02009;&#x02265;&#x02009;0.400, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).<fig id="Fig4"><label>Fig. 4</label><caption><p>Correlation relationship between BRIEF score changes (<bold>A</bold>&#x02013;<bold>C</bold> global executive composite, <bold>D</bold>&#x02013;<bold>F</bold> Metacognition Index) and ADHD Rating Scale score changes for individuals with ADHD who received atomoxetine. GEC, global executive composite; MI, Metacognition Index. Error bar stands for 95% confidence interval</p></caption><graphic xlink:href="12916_2025_4192_Fig4_HTML" id="MO4"/></fig></p><p id="Par64">Regression analyses were also conducted in ATX treatment groups. The results indicated that all baseline measurements (ADHD-RS, BRIEF, WFIRS, cognitive task performances, gender, age, and IQ), when included as independent variables, did not significantly predict the changes of each ADHD core symptom (inattention, hyperactivity/impulsivity, ADHD-RS total score) after multiple comparison corrections with FDR (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p></sec></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par65">This is the first study examining whether digitally targeted cognitive training could enhance the therapeutic effects of medication in children with ADHD. The results indicated that there were no significant differences between M and TCT&#x02009;+&#x02009;M groups in terms of the changes in ADHD core symptoms, ecological executive functions, laboratory cognitive functions, or social functions. After the post-hoc exploratory analysis (TCT&#x02009;+&#x02009;ATX vs. ATX; TCT&#x02009;+&#x02009;MPH vs. MPH), we found that improvements in ADHD core symptoms (including change scores and reduction rates) were more significant in the combination therapy group than in the medication monotherapy group among patients treated with ATX compared to MPH. The improvements in ecological executive functions (GEC and MI) in the TCT&#x02009;+&#x02009;ATX group were significantly greater than in the ATX group. The observed improvements were both significantly correlated with changes in ADHD-RS total and inattention scores. This implies a more pronounced alleviation of symptoms in the TCT&#x02009;+&#x02009;ATX group, possibly attributed to a significant increase in ecological executive functions after combining atomoxetine with targeted cognitive training. However, these results were acquired from post-hoc exploratory analysis instead of our original design, so they should be treated with caution and further validated with more rigorous experimental design.</p><sec id="Sec18"><title>Targeted cognitive training&#x02019;s impact on methylphenidate efficacy in ADHD</title><p id="Par66">In one previous empirical study, the researchers administered 12 consecutive weeks of fixed component cognitive training to 29 ADHD patients receiving stimulant medication. The control group underwent educational training alongside medication treatment. Their results revealed that fixed component cognitive training did not enhance the effects of medication on ADHD core symptoms or cognitive function compared to the control group [<xref ref-type="bibr" rid="CR29">29</xref>]. Although a targeted cognitive training was applied in our study, we still did not observe the promoting effects of it compared to fixed component training in children with ADHD treated with methylphenidate.</p><p id="Par67">This may be due to multiple overlaps between executive function improvements caused by cognitive training and the effects of methylphenidate. Some meta-analyses found that methylphenidate could improve multiple executive function domains in ADHD patients [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Although the observed effect sizes were small to moderate, and the effects were weakened or even disappeared with time [<xref ref-type="bibr" rid="CR32">32</xref>], our study demonstrated that improvements in ecological executive functions in ADHD patients induced by methylphenidate exhibit a substantial effect for a minimum of 8&#x000a0;weeks (refer to Additional file 1: Supplementary Table&#x000a0;3), which may have influenced the capacity to discern any distinct contributions of targeted cognitive training.</p><p id="Par68">Furthermore, recent brain imaging studies have reported notable changes in brain activation within the parietal and frontal regions in ADHD patients following cognitive training [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Remarkably, these changes closely resemble the brain activation patterns observed after methylphenidate treatment in ADHD patients [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. For example, a study found significant changes in the inferior parietal gyrus, middle and inferior frontal gyrus in ADHD patients after 12&#x000a0;weeks of methylphenidate treatment, while patients in the atomoxetine group only had significant activation changes in the left cerebellum [<xref ref-type="bibr" rid="CR37">37</xref>]. In another study that compared changes in brain function and behavioral tasks in ADHD patients after a single dose of methylphenidate or atomoxetine, the findings indicated that both medications had a significant impact on the right middle/superior temporal cortex, posterior cingulate cortex, and precuneus. However, methylphenidate demonstrated an additional effect on the ventrolateral frontal lobe and improved performances in behavioral tasks [<xref ref-type="bibr" rid="CR38">38</xref>]. Given methylphenidate&#x02019;s broad impact on brain activation, its effects may dominate, potentially reducing the capacity to observe additional benefits from cognitive training when combined with medication. Consequently, the potential effects of targeted cognitive training on executive function improvement may be obscured by methylphenidate, leading to no additional benefit for ADHD symptoms.</p></sec><sec id="Sec19"><title>Targeted cognitive training&#x02019;s impact on atomoxetine efficacy in ADHD</title><p id="Par69">In ADHD patients receiving atomoxetine treatment, our study demonstrated that the combination with targeted cognitive training resulted in significantly greater improvements in score changes and reduction rates for ADHD core symptoms compared to the medication monotherapy group. This may be attributed to better improvement in ecological executive function observed in the combination therapy group. This inference is supported by correlation analysis, which revealed that GEC and MI improvements were significantly correlated with some ADHD core symptom improvements. Thus, targeted cognitive training in addition to atomoxetine treatment might result in an additional improvement in ecological executive function in ADHD patients, and this improvement may be effectively transferred to ADHD symptoms.</p><p id="Par70">A recent investigation examined the impact of multidimensional cognitive training compared to medication alone (utilizing either atomoxetine or methylphenidate) on children with ADHD. In this study, 133 patients underwent cognitive training, and 70 individuals who received medication treatment were included. After 12&#x000a0;weeks of intervention, while no significant differences in ADHD core symptom scores were observed between the two groups at post-intervention assessments, notable improvements were found in ecological executive functions, including inhibit, shift, initiate, working memory, plan/organize, and organization of materials in the cognitive training group compared to the medication monotherapy group [<xref ref-type="bibr" rid="CR39">39</xref>]. Thus, cognitive training might possibly improve ecological executive function in ADHD patients and may even be better than medication treatment alone. Furthermore, numerous studies have demonstrated a close association between ecological executive function and ADHD symptoms [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Thus, when combined with cognitive training, which has the potential to enhance ecological executive performance, patients receiving atomoxetine treatment exhibited superior improvements in ADHD symptoms.</p><p id="Par71">We did not find any significant differences in laboratory cognitive function changes between TCT&#x02009;+&#x02009;ATX and ATX groups. Similarly, in a recent ADHD intervention study, significant differences in core symptom changes were found between different treatments (tDCS&#x02009;+&#x02009;cognitive training and sham&#x02009;+&#x02009;cognitive training), yet almost all behavioral task measurements showed no significant between-group differences [<xref ref-type="bibr" rid="CR42">42</xref>], possibly due to the shortcomings of neuropsychological measurements. Potential solutions for future studies may involve employing more sensitive measurement methods, such as neuroelectrophysiology or neuroimaging techniques, along with increasing the sample size, to comprehensively investigate differences in treatment effects. These methods could provide a more in-depth examination of the neural mechanisms of the corresponding symptom changes.</p></sec><sec id="Sec20"><title>The potential clinical implication of targeted cognitive training combined with atomoxetine in children with ADHD</title><p id="Par72">In addition to comparing the combination therapy and medication monotherapy groups, we also assessed the different therapeutic effects of 8&#x000a0;weeks of atomoxetine and methylphenidate in ADHD patients. As shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Additional file 1: Supplementary Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, the average reduction rates of ADHD core symptoms (inattention, MPH&#x02009;=&#x02009;28.5% vs. ATX&#x02009;=&#x02009;23.3%; hyperactivity/impulsivity, MPH&#x02009;=&#x02009;31.9% vs. ATX&#x02009;=&#x02009;18.0%; and total score, MPH&#x02009;=&#x02009;30.4% vs. ATX&#x02009;=&#x02009;21.5%) for methylphenidate were larger than for atomoxetine. This discrepancy could be attributed to the varying effects of different medications on neurotransmitters. Methylphenidate was proved to effectively elevate dopamine concentration in the striatum and prefrontal cortex, as well as increase norepinephrine levels in the prefrontal cortex [<xref ref-type="bibr" rid="CR8">8</xref>]. In contrast, atomoxetine would increase norepinephrine and dopamine levels specifically in the prefrontal cortex but not in the striatum [<xref ref-type="bibr" rid="CR9">9</xref>]. Additionally, the younger age of ADHD patients receiving atomoxetine in this study might have made it challenging to adjust the dosage to match their body weights.</p><p id="Par73">Surprisingly, after combination with targeted cognitive training, the average reduction rates for ADHD core symptoms between the atomoxetine combination group and the methylphenidate monotherapy group were relatively comparable (inattention, TCT&#x02009;+&#x02009;ATX&#x02009;=&#x02009;34.6% vs. MPH&#x02009;=&#x02009;28.5%; hyperactivity/impulsivity, TCT&#x02009;+&#x02009;ATX&#x02009;=&#x02009;34.6% vs. MPH&#x02009;=&#x02009;31.9%; and total score, TCT&#x02009;+&#x02009;ATX&#x02009;=&#x02009;34.3% vs. MPH&#x02009;=&#x02009;30.4%), as shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Supplementary Table&#x000a0;2. Cortese et al. (2018) conducted a review of 81 double-blind, randomized control studies on medication treatment in ADHD. Based on considerations of efficacy and tolerability, they concluded that methylphenidate is the first-choice drug for treating ADHD in children and adolescents [<xref ref-type="bibr" rid="CR4">4</xref>]. While methylphenidate remains a primary treatment option for ADHD, individualized treatment strategies are gaining prominence, particularly for individuals unable to tolerate or benefit from MPH [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In the present study, for ADHD children who received TCT&#x02009;+&#x02009;ATX treatment, the improvements in ADHD core symptoms were comparable to those of children who received methylphenidate. Although atomoxetine was considered secondary to methylphenidate, our results presented an alternative that, when combined with targeted cognitive training, its efficacy may be enhanced.</p><p id="Par74">To address the heterogeneity of cognitive deficits in children with ADHD, the utilization of targeted cognitive training becomes imperative [<xref ref-type="bibr" rid="CR45">45</xref>]. ADHD manifests with a broad range of cognitive impairments, with some children exhibiting deficits in attention, others in working memory, and still others in perception [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. By tailoring cognitive training plans to target specific cognitive weaknesses, such as sustained attention or inhibitory control, individuals can receive interventions that directly address their unique cognitive impairments. The findings from this study have important practical implications for clinical practice in treating children with ADHD. By incorporating targeted cognitive training, interventions can be tailored to meet the specific cognitive needs of each individual, providing individualized and effective treatments that enhance ecological executive functions and alleviate symptoms. This TCT&#x02009;+&#x02009;ATX approach provides a valuable alternative for ADHD children who cannot tolerate methylphenidate, including those with severe tic symptoms, cardiovascular disease, and seizures, and highlights the importance of individualized treatment strategies for effectively managing ADHD symptoms. Clinicians are encouraged to assess the unique cognitive profiles of their patients and consider integrating targeted cognitive training into treatment plans to optimize efficacy.</p></sec><sec id="Sec21"><title>Study strengths and limitations</title><p id="Par75">This study is notable as the first to investigate the impact of integrating digital targeted cognitive training with controlled medication for treating ADHD, offering valuable insights for future research aiming to enhance therapeutic effects for ADHD. Nevertheless, there are some limitations of this study. (1) The sample size of each group was small. In subsequent studies, we will continue to expand the sample size of each group to validate these preliminary results. (2) Due to medication side effects, some children titrated atomoxetine slowly and did not reach the optimal dose during intervention, potentially causing a suboptimal response to atomoxetine treatment within the timeframe. Therefore, it is worth investigating whether these add-on effects of targeted cognitive training on atomoxetine remain in children with ADHD who have reached the optimal dose of atomoxetine. (3) Additionally, in mainland China, only two medications (methylphenidate and atomoxetine) are approved for treating children with ADHD. Consequently, the potential for cognitive training to complement other medications, such as guanfacine, warrants further investigation. (4) There is an absence of long-term follow-up data. Future studies are necessary to determine whether the combined effects of atomoxetine and cognitive training can be sustained. Furthermore, while we did not observe an enhancing effect of targeted cognitive training on ADHD treatment with methylphenidate over 8&#x000a0;weeks, it is conceivable that the benefits of cognitive training may manifest with extended treatment durations. (5) The assessments were limited to subjective questionnaires and laboratory cognitive tasks, which is hard to investigate the neural mechanisms of combining targeted cognitive training with medication. Future studies incorporating electrophysiological and neuroimaging measures could offer additional evidence in this area. (6) The assessments were limited to parent-rated clinical questionnaires, so there was a lack of clinician evaluation in the current study. Future studies should incorporate clinician evaluations such as Clinical Global Impression (CGI). (7) The lack of proper blinding may have introduced bias in this study. Future investigations should implement a double-blind design (to blind participants and the researchers conducting the analysis) and incorporate active control conditions (non-adaptive training).</p></sec></sec><sec id="Sec22"><title>Conclusions</title><p id="Par76">This is the first study examining whether digitally TCT can enhance the therapeutic effects of medications in children with ADHD. The results showed that, compared with medication monotherapy, the intervention combining TCT failed to bring about significant promoting effects on ADHD symptoms. The post-hoc exploratory analysis revealed that this combined treatment only exhibited a significant synergistic effect in the ATX treatment group, but not the MPH group. These results provide a new treatment approach for those children with ADHD who are unable to receive MPH treatment. However, it should be noted that the promoting effects of TCT&#x02009;+&#x02009;ATX on ADHD symptoms in this study were derived from the post-hoc exploratory analysis, rather than our original experimental design. Therefore, whether this result can be generalized still requires further rigorous experimental verification.</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4192_MOESM1_ESM.docx"><caption><p>Additional file 1.&#x000a0;Supplementary Tables 1&#x02013;4. Supplementary Table 1&#x02013;[Demographics and baseline clinical characteristics of the four groups] Supplementary Table 2&#x02013;[Score changes of ADHD-RS inattention, hyperactivity/impulsivity, and total scores at baseline and post-intervention and the corresponding reduction rates across four groups] Supplementary Table 3&#x02013;[Standardized BRIEF scores for global executive composite, two indices, and eight domains at baseline and post-intervention after 8-week treatment across four groups] Supplementary Table 4&#x02013;[Cognitive task performance at baseline and post-intervention across four groups] Supplementary Methods 1&#x02013;3. Supplementary Method 1&#x02013;[Detailed description of cognitive tasks] Supplementary Method 2&#x02013;[Steps to develop personalized training plans] Supplementary Method 3&#x02013;[Elaboration on the assessments used at baseline and post-intervention] Supplementary Fig. 1&#x02013;[Overview of the training procedure].</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ADHD</term><def><p id="Par19">Attention deficit hyperactivity disorder</p></def></def-item><def-item><term>M</term><def><p id="Par20">Medication</p></def></def-item><def-item><term>ATX</term><def><p id="Par21">Atomoxetine</p></def></def-item><def-item><term>MPH</term><def><p id="Par22">Methylphenidate</p></def></def-item><def-item><term>TCT</term><def><p id="Par23">Targeted cognitive training</p></def></def-item><def-item><term>ADHD-RS</term><def><p id="Par24">ADHD Rating Scale</p></def></def-item><def-item><term>K-SADS-PL</term><def><p id="Par25">Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version</p></def></def-item><def-item><term>IQ</term><def><p id="Par26">Intelligence quotient</p></def></def-item><def-item><term>WISC-IV</term><def><p id="Par27">Wechsler Intelligence Scale for Children&#x02014;Fourth Edition</p></def></def-item><def-item><term>BRIEF</term><def><p id="Par28">Behavior Rating Inventory of Executive Function</p></def></def-item><def-item><term>GEC</term><def><p id="Par29">General Executive Composite</p></def></def-item><def-item><term>MI</term><def><p id="Par30">Metacognition Index</p></def></def-item><def-item><term>BRI</term><def><p id="Par31">Behavioral Regulation Index</p></def></def-item><def-item><term>WFIRS</term><def><p id="Par32">Weiss Functional Impairment Rating Scale</p></def></def-item><def-item><term>LMM</term><def><p id="Par33">Linear mixed-effects models</p></def></def-item><def-item><term>FDR</term><def><p id="Par34">False Discovery Rate</p></def></def-item><def-item><term>BHFDR</term><def><p id="Par35">Benjamini-Hochberg procedure</p></def></def-item><def-item><term>LSMDs</term><def><p id="Par36">Least square mean differences</p></def></def-item><def-item><term>CGI</term><def><p id="Par37">Clinical Global Impression</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Chen Dang and Yu Zhu contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors wish to thank the children and their parents for their participation. We also thank Professor Xiaozhen Lv for her valuable advice on statistical analysis.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>CD: design and implementation of study, data analysis, figure plotting, drafting and revising the manuscript. YZ1: figure plotting, drafting and revising the manuscript. XL, LL, YF, GW, SZ, XW1, JZ, YZ2, SL, ZL, LQ, and XM: acquisition of data and revising the manuscript. YW and XW2: supervising the project and revising the manuscript. JY, CW, and LS: design of study, supervising the project, and revising the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work is supported by the Key Scientific Research Projects of Capital Health Development (2020-1-4111), and the National Natural Science Foundation of China (82371549, 81971284, 82271579).</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par77">This study was approved by the ethics committees of Peking University Sixth Hospital (approval number: 2020&#x000ad;6&#x000ad;17&#x000ad;2) and Capital Institute of Pediatrics (approval number: SHERLL2021076). Written informed consent was obtained from all participants and/or their legal guardians prior to participation, in accordance with the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par78">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests
</title><p id="Par79">Li Qin, Xiaohui Ma, and Xiaoyi Wang were employees of the company named Beijing Wispirit Technology Co., Ltd. Other authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association; 2013.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Leckman</surname><given-names>JF</given-names></name></person-group><article-title>Prevalence of mental disorders in school children and adolescents in China: diagnostic data from detailed clinical assessments of 17,524 individuals</article-title><source>J Child Psychol Psychiatry</source><year>2022</year><volume>63</volume><issue>1</issue><fpage>34</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/jcpp.13445</pub-id><?supplied-pmid 34019305?><pub-id pub-id-type="pmid">34019305</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Li F, Cui Y, Li Y, Guo L, Ke X, Liu J, Luo X, Zheng Y, Leckman JF. Prevalence of mental disorders in school children and adolescents in China: diagnostic data from detailed clinical assessments of 17,524 individuals. J Child Psychol Psychiatry. 2022Jan;63(1):34&#x02013;46.=<pub-id pub-id-type="pmid">34019305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>R</given-names></name><name><surname>Balducci</surname><given-names>J</given-names></name><name><surname>Poppi</surname><given-names>C</given-names></name><name><surname>Arcolin</surname><given-names>E</given-names></name><name><surname>Cutino</surname><given-names>A</given-names></name><name><surname>Ferri</surname><given-names>P</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>R</given-names></name><name><surname>Filippini</surname><given-names>T</given-names></name></person-group><article-title>Children and adolescents with ADHD followed up to adulthood: A systematic review of long-term outcomes</article-title><source>Acta Neuropsychiatr</source><year>2021</year><volume>33</volume><issue>6</issue><fpage>283</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1017/neu.2021.23</pub-id><?supplied-pmid 34384511?><pub-id pub-id-type="pmid">34384511</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Di Lorenzo R, Balducci J, Poppi C, Arcolin E, Cutino A, Ferri P, D&#x02019;Amico R, Filippini T. Children and adolescents with ADHD followed up to adulthood: A systematic review of long-term outcomes. Acta Neuropsychiatr. 2021Dec;33(6):283&#x02013;98.<pub-id pub-id-type="pmid">34384511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Sayal</surname><given-names>K</given-names></name><name><surname>Prasad</surname><given-names>V</given-names></name><name><surname>Daley</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>T</given-names></name><name><surname>Coghill</surname><given-names>D</given-names></name></person-group><article-title>ADHD in children and young people: prevalence, care pathways, and service provision</article-title><source>Lancet Psychiatry</source><year>2018</year><volume>5</volume><issue>2</issue><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(17)30167-0</pub-id><?supplied-pmid 29033005?><pub-id pub-id-type="pmid">29033005</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018Feb 1;5(2):175&#x02013;86.<pub-id pub-id-type="pmid">29033005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>J</given-names></name><name><surname>Polanczyk</surname><given-names>GV</given-names></name><name><surname>Sonuga-Barke</surname><given-names>E</given-names></name></person-group><article-title>Attention-deficit hyperactivity disorder</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10222</issue><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)33004-1</pub-id><?supplied-pmid 31982036?><pub-id pub-id-type="pmid">31982036</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020Feb;395(10222):450&#x02013;62.<pub-id pub-id-type="pmid">31982036</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Bolea-Alama&#x000f1;ac</surname><given-names>B</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Adamou</surname><given-names>M</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Bazire</surname><given-names>S</given-names></name><name><surname>Coghill</surname><given-names>D</given-names></name><name><surname>Heal</surname><given-names>D</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U</given-names></name><name><surname>Nash</surname><given-names>J</given-names></name><name><surname>Santosh</surname><given-names>P</given-names></name><name><surname>Sayal</surname><given-names>K</given-names></name></person-group><article-title>Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology</article-title><source>J Psychopharmacol</source><year>2014</year><volume>28</volume><issue>3</issue><fpage>179</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1177/0269881113519509</pub-id><?supplied-pmid 24526134?><pub-id pub-id-type="pmid">24526134</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bolea-Alama&#x000f1;ac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, Heal D, M&#x000fc;ller U, Nash J, Santosh P, Sayal K. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014Mar;28(3):179&#x02013;203.<pub-id pub-id-type="pmid">24526134</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolraich</surname><given-names>ML</given-names></name><name><surname>Hagan</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Allan</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Davison</surname><given-names>D</given-names></name><name><surname>Earls</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>SW</given-names></name><name><surname>Flinn</surname><given-names>SK</given-names></name><name><surname>Froehlich</surname><given-names>T</given-names></name><name><surname>Frost</surname><given-names>J</given-names></name><name><surname>Holbrook</surname><given-names>JR</given-names></name></person-group><article-title>Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents</article-title><source>Pediatrics.</source><year>2019</year><volume>144</volume><issue>4</issue><fpage>e20192528</fpage><pub-id pub-id-type="doi">10.1542/peds.2019-2528</pub-id><?supplied-pmid 31570648?><pub-id pub-id-type="pmid">31570648</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.<pub-id pub-id-type="pmid">31570648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Del Campo</surname><given-names>N</given-names></name><name><surname>Chamberlain</surname><given-names>SR</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><issue>12</issue><fpage>e145</fpage><lpage>e157</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.02.036</pub-id><?supplied-pmid 21550021?><pub-id pub-id-type="pmid">21550021</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011Jun 15;69(12):e145&#x02013;57.<pub-id pub-id-type="pmid">21550021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>DD</given-names></name><name><surname>Guo</surname><given-names>HL</given-names></name><name><surname>Hu</surname><given-names>YH</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>WR</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>QQ</given-names></name></person-group><article-title>The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: a narrative review</article-title><source>Front Psychiatry</source><year>2022</year><volume>9</volume><issue>12</issue><fpage>780921</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2021.780921</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Fu D, Wu DD, Guo HL, Hu YH, Xia Y, Ji X, Fang WR, Li YM, Xu J, Chen F, Liu QQ. The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: a narrative review. Front Psychiatry. 2022Feb;9(12): 780921.</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gayleard</surname><given-names>JL</given-names></name><name><surname>Mychailyszyn</surname><given-names>MP</given-names></name></person-group><article-title>Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology</article-title><source>Atten Defic Hyperact Disord</source><year>2017</year><volume>9</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s12402-017-0216-y</pub-id><?supplied-pmid 28110366?><pub-id pub-id-type="pmid">28110366</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gayleard JL, Mychailyszyn MP. Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology. Atten Defic Hyperact Disord. 2017Sep;9:149&#x02013;60.<pub-id pub-id-type="pmid">28110366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Adamo</surname><given-names>N</given-names></name><name><surname>Del Giovane</surname><given-names>C</given-names></name><name><surname>Mohr-Jensen</surname><given-names>C</given-names></name><name><surname>Hayes</surname><given-names>AJ</given-names></name><name><surname>Carucci</surname><given-names>S</given-names></name><name><surname>Atkinson</surname><given-names>LZ</given-names></name><name><surname>Tessari</surname><given-names>L</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Coghill</surname><given-names>D</given-names></name><name><surname>Hollis</surname><given-names>C</given-names></name></person-group><article-title>Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis</article-title><source>Lancet Psychiatry</source><year>2018</year><volume>5</volume><issue>9</issue><fpage>727</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(18)30269-4</pub-id><?supplied-pmid 30097390?><pub-id pub-id-type="pmid">30097390</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018Sep 1;5(9):727&#x02013;38.<pub-id pub-id-type="pmid">30097390</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Pievsky</surname><given-names>MA</given-names></name><name><surname>McGrath</surname><given-names>RE</given-names></name></person-group><article-title>Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis</article-title><source>Neurosci Biobehav Rev</source><year>2018</year><volume>1</volume><issue>90</issue><fpage>447</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.05.012</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Pievsky MA, McGrath RE. Neurocognitive effects of methylphenidate in adults with attention-deficit/hyperactivity disorder: A meta-analysis. Neurosci Biobehav Rev. 2018Jul;1(90):447&#x02013;55.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Tamminga</surname><given-names>HG</given-names></name><name><surname>Reneman</surname><given-names>L</given-names></name><name><surname>Huizenga</surname><given-names>HM</given-names></name><name><surname>Geurts</surname><given-names>HM</given-names></name></person-group><article-title>Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis</article-title><source>Psychol Med</source><year>2016</year><volume>46</volume><issue>9</issue><fpage>1791</fpage><lpage>1807</lpage><pub-id pub-id-type="doi">10.1017/S0033291716000350</pub-id><?supplied-pmid 27019103?><pub-id pub-id-type="pmid">27019103</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tamminga HG, Reneman L, Huizenga HM, Geurts HM. Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. Psychol Med. 2016Jul;46(9):1791&#x02013;807.<pub-id pub-id-type="pmid">27019103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Vertessen</surname><given-names>K</given-names></name><name><surname>Luman</surname><given-names>M</given-names></name><name><surname>Staff</surname><given-names>A</given-names></name><name><surname>Bet</surname><given-names>P</given-names></name><name><surname>de Vries</surname><given-names>R</given-names></name><name><surname>Twisk</surname><given-names>J</given-names></name><name><surname>Oosterlaan</surname><given-names>J</given-names></name></person-group><article-title>Meta-analysis: Dose-dependent effects of methylphenidate on neurocognitive functioning in children with attention-deficit/hyperactivity disorder</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2022</year><volume>61</volume><issue>5</issue><fpage>626</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2021.08.023</pub-id><?supplied-pmid 34534624?><pub-id pub-id-type="pmid">34534624</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Vertessen K, Luman M, Staff A, Bet P, de Vries R, Twisk J, Oosterlaan J. Meta-analysis: Dose-dependent effects of methylphenidate on neurocognitive functioning in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2022May 1;61(5):626&#x02013;46.<pub-id pub-id-type="pmid">34534624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zuschlag</surname><given-names>ZD</given-names></name><name><surname>Myers</surname><given-names>US</given-names></name><name><surname>Hamner</surname><given-names>M</given-names></name></person-group><article-title>Atomoxetine in comorbid ADHD/PTSD: a randomized, placebo controlled, pilot, and feasibility study</article-title><source>Depress Anxiety</source><year>2022</year><volume>39</volume><issue>4</issue><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1002/da.23248</pub-id><?supplied-pmid 35312136?><pub-id pub-id-type="pmid">35312136</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wang Z, Zuschlag ZD, Myers US, Hamner M. Atomoxetine in comorbid ADHD/PTSD: a randomized, placebo controlled, pilot, and feasibility study. Depress Anxiety. 2022Apr;39(4):286&#x02013;95.<pub-id pub-id-type="pmid">35312136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeggi</surname><given-names>SM</given-names></name><name><surname>Buschkuehl</surname><given-names>M</given-names></name><name><surname>Jonides</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name></person-group><article-title>Short-and long-term benefits of cognitive training</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><issue>25</issue><fpage>10081</fpage><lpage>10086</lpage><pub-id pub-id-type="doi">10.1073/pnas.1103228108</pub-id><?supplied-pmid 21670271?><pub-id pub-id-type="pmid">21670271</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Jaeggi SM, Buschkuehl M, Jonides J, Shah P. Short-and long-term benefits of cognitive training. Proc Natl Acad Sci U S A. 2011Jun 21;108(25):10081&#x02013;6.<pub-id pub-id-type="pmid">21670271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Keshavan</surname><given-names>MS</given-names></name><name><surname>Vinogradov</surname><given-names>S</given-names></name><name><surname>Rumsey</surname><given-names>J</given-names></name><name><surname>Sherrill</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name></person-group><article-title>Cognitive training in mental disorders: update and future directions</article-title><source>Am J Psychiatry</source><year>2014</year><volume>171</volume><issue>5</issue><fpage>510</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13081075</pub-id><?supplied-pmid 24700194?><pub-id pub-id-type="pmid">24700194</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Keshavan MS, Vinogradov S, Rumsey J, Sherrill J, Wagner A. Cognitive training in mental disorders: update and future directions. Am J Psychiatry. 2014May;171(5):510&#x02013;22.<pub-id pub-id-type="pmid">24700194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Ferrin</surname><given-names>M</given-names></name><name><surname>Brandeis</surname><given-names>D</given-names></name><name><surname>Buitelaar</surname><given-names>J</given-names></name><name><surname>Daley</surname><given-names>D</given-names></name><name><surname>Dittmann</surname><given-names>RW</given-names></name><name><surname>Holtmann</surname><given-names>M</given-names></name><name><surname>Santosh</surname><given-names>P</given-names></name><name><surname>Stevenson</surname><given-names>J</given-names></name><name><surname>Stringaris</surname><given-names>A</given-names></name><name><surname>Zuddas</surname><given-names>A</given-names></name></person-group><article-title>Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2015</year><volume>54</volume><issue>3</issue><fpage>164</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2014.12.010</pub-id><?supplied-pmid 25721181?><pub-id pub-id-type="pmid">25721181</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, Holtmann M, Santosh P, Stevenson J, Stringaris A, Zuddas A. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015Mar 1;54(3):164&#x02013;74.<pub-id pub-id-type="pmid">25721181</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Westwood</surname><given-names>SJ</given-names></name><name><surname>Parlatini</surname><given-names>V</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Sonuga-Barke</surname><given-names>EJ</given-names></name></person-group><article-title>Computerized cognitive training in attention-deficit/hyperactivity disorder (ADHD): a meta-analysis of randomized controlled trials with blinded and objective outcomes</article-title><source>Mol Psychiatry</source><year>2023</year><volume>28</volume><issue>4</issue><fpage>1402</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-02000-7</pub-id><?supplied-pmid 36977764?><pub-id pub-id-type="pmid">36977764</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Westwood SJ, Parlatini V, Rubia K, Cortese S, Sonuga-Barke EJ. Computerized cognitive training in attention-deficit/hyperactivity disorder (ADHD): a meta-analysis of randomized controlled trials with blinded and objective outcomes. Mol Psychiatry. 2023Apr;28(4):1402&#x02013;14.<pub-id pub-id-type="pmid">36977764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Coghill</surname><given-names>DR</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>K</given-names></name></person-group><article-title>A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models</article-title><source>Psychol Med</source><year>2014</year><volume>44</volume><issue>9</issue><fpage>1989</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1017/S0033291713002547</pub-id><?supplied-pmid 24176104?><pub-id pub-id-type="pmid">24176104</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Coghill DR, Seth S, Matthews K. A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. Psychol Med. 2014Jul;44(9):1989&#x02013;2001.<pub-id pub-id-type="pmid">24176104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name></person-group><article-title>Computer-based multiple component cognitive training in children with ADHD: a pilot study</article-title><source>Child Adolesc Psychiatry Ment Health</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s13034-022-00553-z</pub-id><?supplied-pmid 36647166?><pub-id pub-id-type="pmid">36647166</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wu Y, Xu L, Wu Z, Cao X, Xue G, Wang Y, Yang B. Computer-based multiple component cognitive training in children with ADHD: a pilot study. Child Adolesc Psychiatry Ment Health. 2023Jan 16;17(1):9.<pub-id pub-id-type="pmid">36647166</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>McClure</surname><given-names>MM</given-names></name><name><surname>Graff</surname><given-names>F</given-names></name><name><surname>Triebwasser</surname><given-names>J</given-names></name><name><surname>Perez-Rodriguez</surname><given-names>M</given-names></name><name><surname>Rosell</surname><given-names>DR</given-names></name><name><surname>Koenigsberg</surname><given-names>H</given-names></name><name><surname>Hazlett</surname><given-names>EA</given-names></name><name><surname>Siever</surname><given-names>LJ</given-names></name><name><surname>Harvey</surname><given-names>PD</given-names></name><name><surname>New</surname><given-names>AS</given-names></name></person-group><article-title>Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder</article-title><source>Am J Psychiatry</source><year>2019</year><volume>176</volume><issue>4</issue><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2018.18030349</pub-id><?supplied-pmid 30654644?><pub-id pub-id-type="pmid">30654644</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">McClure MM, Graff F, Triebwasser J, Perez-Rodriguez M, Rosell DR, Koenigsberg H, Hazlett EA, Siever LJ, Harvey PD, New AS. Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder. Am J Psychiatry. 2019Apr 1;176(4):307&#x02013;14.<pub-id pub-id-type="pmid">30654644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Yesavage J, Hoblyn J, Friedman L, Mumenthaler M, Schneider B, O'Hara R. Should one use medications in combination with cognitive training? If so, which ones?. J Gerontol B Psychol Sci Soc Sci. 2007 Jun 1;62(Special_Issue_1):11&#x02013;8.</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Kollins</surname><given-names>SH</given-names></name><name><surname>DeLoss</surname><given-names>DJ</given-names></name><name><surname>Ca&#x000f1;adas</surname><given-names>E</given-names></name><name><surname>Lutz</surname><given-names>J</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Keefe</surname><given-names>RS</given-names></name><name><surname>Epstein</surname><given-names>JN</given-names></name><name><surname>Cutler</surname><given-names>AJ</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial</article-title><source>Lancet Digit Health</source><year>2020</year><volume>2</volume><issue>4</issue><fpage>e168</fpage><lpage>e178</lpage><pub-id pub-id-type="doi">10.1016/S2589-7500(20)30017-0</pub-id><?supplied-pmid 33334505?><pub-id pub-id-type="pmid">33334505</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Kollins SH, DeLoss DJ, Ca&#x000f1;adas E, Lutz J, Findling RL, Keefe RS, Epstein JN, Cutler AJ, Faraone SV. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Health. 2020Apr 1;2(4):e168&#x02013;78.<pub-id pub-id-type="pmid">33334505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Johnstone</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><article-title>A randomized controlled study of remote computerized cognitive, neurofeedback, and combined training in the treatment of children with attention-deficit/hyperactivity disorder</article-title><source>Eur Child Adolesc Psychiatry</source><year>2023</year><volume>32</volume><issue>8</issue><fpage>1475</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1007/s00787-022-01956-1</pub-id><?supplied-pmid 35182242?><pub-id pub-id-type="pmid">35182242</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Luo X, Guo X, Zhao Q, Zhu Y, Chen Y, Zhang D, Jiang H, Wang Y, Johnstone S, Sun L. A randomized controlled study of remote computerized cognitive, neurofeedback, and combined training in the treatment of children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2023Aug;32(8):1475&#x02013;86.<pub-id pub-id-type="pmid">35182242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Makransky</surname><given-names>G</given-names></name><name><surname>Bilenberg</surname><given-names>N</given-names></name></person-group><article-title>Psychometric properties of the parent and teacher ADHD Rating Scale (ADHD-RS) measurement invariance across gender, age, and informant</article-title><source>Assessment</source><year>2014</year><volume>21</volume><issue>6</issue><fpage>694</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1177/1073191114535242</pub-id><?supplied-pmid 24852496?><pub-id pub-id-type="pmid">24852496</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Makransky G, Bilenberg N. Psychometric properties of the parent and teacher ADHD Rating Scale (ADHD-RS) measurement invariance across gender, age, and informant. Assessment. 2014Dec;21(6):694&#x02013;705.<pub-id pub-id-type="pmid">24852496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Gioia</surname><given-names>GA</given-names></name><name><surname>Guy</surname><given-names>SC</given-names></name><name><surname>Kenworthy</surname><given-names>L</given-names></name></person-group><article-title>Behavior rating inventory of executive function</article-title><source>Child Neuropsychol.</source><year>2000</year><volume>6</volume><issue>3</issue><fpage>235</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1076/chin.6.3.235.3152</pub-id><pub-id pub-id-type="pmid">11419452</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gioia GA, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Child Neuropsychol. 2000;6(3):235&#x02013;8.<pub-id pub-id-type="pmid">11419452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Weiss MD, Brooks BL, Iverson GL, Lee B, Dickson R, Wasdell M. Reliability and validity of the Weiss functional impairment rating scale. In AACAP 54th annual meeting, Boston, MA 2007 Oct 23 (pp. 23&#x02013;28).</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>RV</given-names></name><name><surname>Moreira-Maia</surname><given-names>CR</given-names></name><name><surname>Wagner</surname><given-names>F</given-names></name><name><surname>Simioni</surname><given-names>A</given-names></name><name><surname>de Fraga</surname><given-names>BC</given-names></name><name><surname>Moritz</surname><given-names>GR</given-names></name><name><surname>Schmitz</surname><given-names>M</given-names></name><name><surname>Rohde</surname><given-names>LA</given-names></name></person-group><article-title>Computerized cognitive training for ADHD as an add-on treatment to stimulants: A randomized clinical trial</article-title><source>J Atten Disord</source><year>2021</year><volume>25</volume><issue>2</issue><fpage>275</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1177/1087054718816818</pub-id><pub-id pub-id-type="pmid">30547696</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">de Oliveira RV, Moreira-Maia CR, Wagner F, Simioni A, de Fraga BC, Moritz GR, Schmitz M, Rohde LA. Computerized cognitive training for ADHD as an add-on treatment to stimulants: A randomized clinical trial. J Atten Disord. 2021Jan;25(2):275&#x02013;85.<pub-id pub-id-type="pmid">30547696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Coghill</surname><given-names>DR</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Pedroso</surname><given-names>S</given-names></name><name><surname>Usala</surname><given-names>T</given-names></name><name><surname>Currie</surname><given-names>J</given-names></name><name><surname>Gagliano</surname><given-names>A</given-names></name></person-group><article-title>Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis</article-title><source>Biol Psychiatry</source><year>2014</year><volume>76</volume><issue>8</issue><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.10.005</pub-id><?supplied-pmid 24231201?><pub-id pub-id-type="pmid">24231201</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Coghill DR, Seth S, Pedroso S, Usala T, Currie J, Gagliano A. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry. 2014Oct 15;76(8):603&#x02013;15.<pub-id pub-id-type="pmid">24231201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Mckenzie</surname><given-names>A</given-names></name><name><surname>Meshkat</surname><given-names>S</given-names></name><name><surname>Lui</surname><given-names>LM</given-names></name><name><surname>Ho</surname><given-names>R</given-names></name><name><surname>Di Vincenzo</surname><given-names>JD</given-names></name><name><surname>Ceban</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name></person-group><article-title>The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review</article-title><source>J Psychiatr Res</source><year>2022</year><volume>1</volume><issue>149</issue><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2022.03.018</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Mckenzie A, Meshkat S, Lui LM, Ho R, Di Vincenzo JD, Ceban F, Cao B, McIntyre RS. The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: A systematic review. J Psychiatr Res. 2022May;1(149):252&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tamminga</surname><given-names>HG</given-names></name><name><surname>Reneman</surname><given-names>L</given-names></name><name><surname>Schrantee</surname><given-names>A</given-names></name><name><surname>Bottelier</surname><given-names>MA</given-names></name><name><surname>Bouziane</surname><given-names>C</given-names></name><name><surname>Geurts</surname><given-names>HM</given-names></name><name><surname>Groenman</surname><given-names>AP</given-names></name></person-group><article-title>Do effects of methylphenidate on cognitive performance last beyond treatment? A randomized placebo-controlled trial in boys and men with ADHD</article-title><source>Eur Neuropsychopharmacol</source><year>2021</year><volume>1</volume><issue>46</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2021.02.002</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tamminga HG, Reneman L, Schrantee A, Bottelier MA, Bouziane C, Geurts HM, Groenman AP. Do effects of methylphenidate on cognitive performance last beyond treatment? A randomized placebo-controlled trial in boys and men with ADHD. Eur Neuropsychopharmacol. 2021May;1(46):1&#x02013;3.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Salmi</surname><given-names>J</given-names></name><name><surname>Soveri</surname><given-names>A</given-names></name><name><surname>Salmela</surname><given-names>V</given-names></name><name><surname>Alho</surname><given-names>K</given-names></name><name><surname>Lepp&#x000e4;m&#x000e4;ki</surname><given-names>S</given-names></name><name><surname>Tani</surname><given-names>P</given-names></name><name><surname>Koski</surname><given-names>A</given-names></name><name><surname>Jaeggi</surname><given-names>SM</given-names></name><name><surname>Laine</surname><given-names>M</given-names></name></person-group><article-title>Working memory training restores aberrant brain activity in adult attention-deficit hyperactivity disorder</article-title><source>Hum Brain Mapp</source><year>2020</year><volume>41</volume><issue>17</issue><fpage>4876</fpage><lpage>4891</lpage><pub-id pub-id-type="doi">10.1002/hbm.25164</pub-id><?supplied-pmid 32813290?><pub-id pub-id-type="pmid">32813290</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Salmi J, Soveri A, Salmela V, Alho K, Lepp&#x000e4;m&#x000e4;ki S, Tani P, Koski A, Jaeggi SM, Laine M. Working memory training restores aberrant brain activity in adult attention-deficit hyperactivity disorder. Hum Brain Mapp. 2020Dec 1;41(17):4876&#x02013;91.<pub-id pub-id-type="pmid">32813290</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoekzema</surname><given-names>E</given-names></name><name><surname>Carmona</surname><given-names>S</given-names></name><name><surname>Tremols</surname><given-names>V</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><name><surname>Guitart</surname><given-names>M</given-names></name><name><surname>Fauquet</surname><given-names>J</given-names></name><name><surname>Rovira</surname><given-names>M</given-names></name><name><surname>Bielsa</surname><given-names>A</given-names></name><name><surname>Soliva</surname><given-names>JC</given-names></name><name><surname>Tomas</surname><given-names>X</given-names></name><name><surname>Bulbena</surname><given-names>A</given-names></name></person-group><article-title>Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attention-deficit/hyperactivity disorder</article-title><source>Hum Brain Mapp</source><year>2010</year><volume>31</volume><issue>12</issue><fpage>1942</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.1002/hbm.20988</pub-id><?supplied-pmid 20336653?><pub-id pub-id-type="pmid">20336653</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hoekzema E, Carmona S, Tremols V, Gispert JD, Guitart M, Fauquet J, Rovira M, Bielsa A, Soliva JC, Tomas X, Bulbena A. Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attention-deficit/hyperactivity disorder. Hum Brain Mapp. 2010Dec;31(12):1942&#x02013;50.<pub-id pub-id-type="pmid">20336653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubia</surname><given-names>K</given-names></name><name><surname>Halari</surname><given-names>R</given-names></name><name><surname>Mohammad</surname><given-names>AM</given-names></name><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name></person-group><article-title>Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder</article-title><source>Biol psychiatry</source><year>2011</year><volume>70</volume><issue>3</issue><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.04.018</pub-id><?supplied-pmid 21664605?><pub-id pub-id-type="pmid">21664605</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Rubia K, Halari R, Mohammad AM, Taylor E, Brammer M. Methylphenidate normalizes frontocingulate underactivation during error processing in attention-deficit/hyperactivity disorder. Biol psychiatry. 2011Aug 1;70(3):255&#x02013;62.<pub-id pub-id-type="pmid">21664605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Czerniak</surname><given-names>SM</given-names></name><name><surname>Sikoglu</surname><given-names>EM</given-names></name><name><surname>King</surname><given-names>JA</given-names></name><name><surname>Kennedy</surname><given-names>DN</given-names></name><name><surname>Mick</surname><given-names>E</given-names></name><name><surname>Frazier</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>CM</given-names></name></person-group><article-title>Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review</article-title><source>Harv Rev Psychiatry</source><year>2013</year><volume>21</volume><issue>3</issue><fpage>151</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1097/HRP.0b013e318293749e</pub-id><?supplied-pmid 23660970?><pub-id pub-id-type="pmid">23660970</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Czerniak SM, Sikoglu EM, King JA, Kennedy DN, Mick E, Frazier J, Moore CM. Areas of the brain modulated by single-dose methylphenidate treatment in youth with ADHD during task-based fMRI: a systematic review. Harv Rev Psychiatry. 2013May 1;21(3):151&#x02013;62.<pub-id pub-id-type="pmid">23660970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name></person-group><article-title>Shared and unique effects of long-term administration of methylphenidate and atomoxetine on degree centrality in medication-na&#x000ef;ve children with attention-deficit/hyperactive disorder</article-title><source>Int J Neuropsychopharmacol</source><year>2022</year><volume>25</volume><issue>9</issue><fpage>709</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyac028</pub-id><?supplied-pmid 35524732?><pub-id pub-id-type="pmid">35524732</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Fu Z, Yuan J, Pei X, Zhang K, Xu C, Hu N, Xie R, Zhao Y, Wang Y, Yang L, Cao Q. Shared and unique effects of long-term administration of methylphenidate and atomoxetine on degree centrality in medication-na&#x000ef;ve children with attention-deficit/hyperactive disorder. Int J Neuropsychopharmacol. 2022Sep 1;25(9):709&#x02013;19.<pub-id pub-id-type="pmid">35524732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Kowalczyk</surname><given-names>OS</given-names></name><name><surname>Cubillo</surname><given-names>AI</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Barrett</surname><given-names>N</given-names></name><name><surname>Giampietro</surname><given-names>V</given-names></name><name><surname>Brammer</surname><given-names>M</given-names></name><name><surname>Simmons</surname><given-names>A</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents</article-title><source>Eur Neuropsychopharmacol</source><year>2019</year><volume>29</volume><issue>10</issue><fpage>1102</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2019.07.139</pub-id><?supplied-pmid 31358436?><pub-id pub-id-type="pmid">31358436</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kowalczyk OS, Cubillo AI, Smith A, Barrett N, Giampietro V, Brammer M, Simmons A, Rubia K. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019Oct 1;29(10):1102&#x02013;16.<pub-id pub-id-type="pmid">31358436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Geng</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name></person-group><article-title>Efficacy of digital multi-dimensional parent-child training for children with attention deficit hyperactivity disorder: a controlled clinical study</article-title><source>Chinese Journal of Psychaitry</source><year>2023</year><volume>56</volume><issue>6</issue><fpage>435</fpage><lpage>444</lpage></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zheng R, Geng F, Yang Y, Liu H, Zheng Y. Efficacy of digital multi-dimensional parent-child training for children with attention deficit hyperactivity disorder: a controlled clinical study. Chinese Journal of Psychaitry. 2023Dec 5;56(6):435&#x02013;44 (<bold>[in Chinese]</bold>).</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>MJ</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Leon</surname><given-names>TL</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Adler</surname><given-names>LA</given-names></name></person-group><article-title>The Relationship Between Executive Function Deficits and DSM-5-Defined ADHD Symptoms</article-title><source>J Atten Disord</source><year>2020</year><volume>24</volume><issue>1</issue><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1177/1087054718804347</pub-id><?supplied-pmid 30296883?><pub-id pub-id-type="pmid">30296883</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Silverstein MJ, Faraone SV, Leon TL, Biederman J, Spencer TJ, Adler LA. The Relationship Between Executive Function Deficits and DSM-5-Defined ADHD Symptoms. J Atten Disord. 2020;24(1):41&#x02013;51.<pub-id pub-id-type="pmid">30296883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>DiSalvo</surname><given-names>ML</given-names></name><name><surname>Vater</surname><given-names>CRH</given-names></name><name><surname>Woodworth</surname><given-names>KY</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>Toward operationalizing executive function deficits in adults with ADHD using the Behavior Rating Inventory of Executive Function&#x02014;Adult Version (BRIEF-A)</article-title><source>J Clin Psychiatry</source><year>2022</year><volume>84</volume><issue>1</issue><fpage>44163</fpage><pub-id pub-id-type="doi">10.4088/JCP.22m14530</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Biederman J, DiSalvo ML, Vater CRH, Woodworth KY, Faraone SV. Toward operationalizing executive function deficits in adults with ADHD using the Behavior Rating Inventory of Executive Function&#x02014;Adult Version (BRIEF-A). J Clin Psychiatry. 2022;84(1):44163.</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Westwood</surname><given-names>SJ</given-names></name><name><surname>Criaud</surname><given-names>M</given-names></name><name><surname>Lam</surname><given-names>SL</given-names></name><name><surname>Lukito</surname><given-names>S</given-names></name><name><surname>Wallace-Hanlon</surname><given-names>S</given-names></name><name><surname>Kowalczyk</surname><given-names>OS</given-names></name><etal/></person-group><article-title>Transcranial direct current stimulation (tDCS) combined with cognitive training in adolescent boys with ADHD: a double-blind, randomised, sham-controlled trial</article-title><source>Psychol Medicine</source><year>2023</year><volume>53</volume><issue>2</issue><fpage>497</fpage><lpage>512</lpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Westwood SJ, Criaud M, Lam SL, Lukito S, Wallace-Hanlon S, Kowalczyk OS, et al. Transcranial direct current stimulation (tDCS) combined with cognitive training in adolescent boys with ADHD: a double-blind, randomised, sham-controlled trial. Psychol Medicine. 2023;53(2):497&#x02013;512.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Krinzinger</surname><given-names>H</given-names></name><name><surname>Hall</surname><given-names>CL</given-names></name><name><surname>Groom</surname><given-names>MJ</given-names></name><name><surname>Ansari</surname><given-names>MT</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence</article-title><source>Neurosci Biobehav Rev</source><year>2019</year><volume>107</volume><fpage>945</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.09.023</pub-id><?supplied-pmid 31545988?><pub-id pub-id-type="pmid">31545988</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Krinzinger H, Hall CL, Groom MJ, Ansari MT, Banaschewski T, Buitelaar JK, et al. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev. 2019;107:945&#x02013;68.<pub-id pub-id-type="pmid">31545988</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Shim SH, Yoon H jung, Bak J, Hahn SW, Kim YK. Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:237&#x02013;44.</mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Minder</surname><given-names>F</given-names></name><name><surname>Zuberer</surname><given-names>A</given-names></name><name><surname>Brandeis</surname><given-names>D</given-names></name><name><surname>Drechsler</surname><given-names>R</given-names></name></person-group><article-title>Specific effects of individualized cognitive training in children with attention-deficit/hyperactivity disorder (ADHD): The role of pre-training cognitive impairment and individual training performance</article-title><source>Dev Neurorehabil</source><year>2019</year><volume>22</volume><issue>6</issue><fpage>400</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1080/17518423.2019.1600064</pub-id><?supplied-pmid 31021250?><pub-id pub-id-type="pmid">31021250</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Minder F, Zuberer A, Brandeis D, Drechsler R. Specific effects of individualized cognitive training in children with attention-deficit/hyperactivity disorder (ADHD): The role of pre-training cognitive impairment and individual training performance. Dev Neurorehabil. 2019;22(6):400&#x02013;14.<pub-id pub-id-type="pmid">31021250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Fuermaier</surname><given-names>AB</given-names></name><name><surname>H&#x000fc;pen</surname><given-names>P</given-names></name><name><surname>De Vries</surname><given-names>SM</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Kok</surname><given-names>FM</given-names></name><name><surname>Koerts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Perception in attention deficit hyperactivity disorder</article-title><source>Atten Defic Hyperact Disord</source><year>2018</year><volume>10</volume><fpage>21</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s12402-017-0230-0</pub-id><?supplied-pmid 28401487?><pub-id pub-id-type="pmid">28401487</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Fuermaier AB, H&#x000fc;pen P, De Vries SM, M&#x000fc;ller M, Kok FM, Koerts J, et al. Perception in attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2018;10:21&#x02013;47.<pub-id pub-id-type="pmid">28401487</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>